CRISPR, Caffeine Switches, and Biotech Deals
Kilder
- BioPharma Dive: Incyte to buy blood disorder drug in possibly $2B deal
- Finance: Incyte strikes up to $2 billion deal for Star Therapeutics' subsidiary - Yahoo Finance
- Financial Times: Incyte strikes up to $2bn deal for blood disorder biotech - Financial Times
- Labiotech: Top biotech deals in May 2026
- Fierce Biotech: Why the Central Laboratory is Becoming a Defining Advantage in Modern Clinical Trials
- BioPharma Dive: Innovation alone is no longer enough in biopharma
- Economictimes: How AI companies are using industry recognition to build credibility and growth - The Economic Times
- Fierce Biotech: The Future of Medicine is Built in Ohio
Oppsummeringen og talen er laget med KI. Kildelenkene viser opphavet og er ikke en anbefaling av TellMe fra mediene.